Second-line treatment with ramucirumab plus docetaxel extends survival in advanced NSCLC

Bookmark and Share
Published: 31 May 2014
Views: 3029
Dr Maurice Pérol - Centre Léon Bérard, Lyon, France

At a press conference at ASCO 2014, Dr Pérol presents the findings from the REVEL phase III study of patients with stage IV non -small cell lung cancer (NSCLC) which indicate that a combination of a new anti-angiogenesis drug, ramucirumab, and standard docetaxel chemotherapy extends overall survival for patients who have a relapse after initial treatment compared to docetaxel plus placebo.

Read the article for more.